Cerenome, Inc. (CNSY) stock
CNSYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/3071% below fair value
$0.71+0.08 (+12.14%)
Close on Nov 18, 2026Market cap $5.36MP/E –Yield –
Cerenome price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Cerenome's price to sales ratio was 1.4× on Nov 11, 2026, against 15.3× a year earlier. Over the last 5 years it ranged from 0.0× to 192.7×, with a median of 0.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.4× | −11.4 |
| 2025 | Dec 31, 2025 | 12.8× | +12.8 |
| 2019 | Oct 31, 2019 | 0.0× | −0.1 |
| 2018 | Dec 31, 2018 | 0.1× | −0.1 |
| 2017 | Dec 29, 2017 | 0.2× | −0.2 |
| 2016 | Dec 30, 2016 | 0.4× | – |
See a number that looks wrong?